3D-Printed Pimobendan for Dogs: Custom Dosage Study

3D-Printed Pimobendan Tablets: A First-in-Dog Pharmacokinetic Trial

For dogs with congestive heart failure, the drug pimobendan is a standard of care. A new study from Brazilian universities, published in Drug Delivery and Translational Research, moves a novel 3D-printed version of this medication from the laboratory to live animals. The clinical trial with beagle dogs provides evidence that 3D printing can create viable, safe tablets and offers a new method to customize doses for individual patients.

From Lab Prototype to Canine Bloodstream

The team, led by J. Leão from the Federal University of Rio Grande do Sul, used a method called semisolid extrusion 3D printing. They fabricated small tablets, or “printlets,” each containing 2.5 mg of pimobendan. These were compared head-to-head against the widely used commercial chewable tablet, Vetmedin®. Researchers first confirmed the printlets met standards for weight, drug content, and dissolution. Then came the crucial test: orally administering a single 0.2 mg/kg dose to healthy beagle dogs.

The primary goal was to track how the body processes the drug—its pharmacokinetics. Using sensitive LC-MS/MS analysis, scientists measured pimobendan levels in the dogs’ plasma over time. The results showed both formulations delivered the drug into the bloodstream, but not in the same way. The 3D-printed tablets exhibited what the paper describes as a “sustained release profile.” This indicates the printed formulation released pimobendan more gradually over a longer period compared to the quicker release of the commercial tablet. Importantly, no adverse effects were observed from the printed tablets during the study.

Addressing Real-World Problems in Canine Cardiac Care

This finding matters because it directly tackles two practical issues veterinarians and pet owners face. First, pimobendan is often prescribed for small-breed dogs like Cavalier King Charles Spaniels and Dachshunds, which are predisposed to mitral valve disease. The available tablet strengths can make precise, weight-based dosing challenging, especially for tiny patients. Second, some dogs resist taking large pills. 3D printing enables the creation of smaller, potentially more palatable tablets at exact, tailored dosages.

The study’s authors explicitly note that current commercial formulations have “restricted dose flexibility and large tablet sizes, which may compromise long-term treatment individualisation.” Customizable 3D printing could allow a veterinarian to prescribe, for example, a 1.7 mg or a 3.3 mg tablet exactly suited to a patient’s calculated needs, improving treatment accuracy and ease of administration. This level of personalization is a significant step beyond simply splitting commercially available pills, which can lead to inaccurate dosing.

The Road Ahead for Personalized Veterinary Medicine

This research provides a proof-of-concept that additive manufacturing has a place in veterinary pharmacies. However, the study was conducted in healthy dogs. The critical next step is to evaluate the 3D-printed pimobendan’s effectiveness and safety in dogs actually diagnosed with heart failure. Furthermore, the pharmacokinetic differences noted—the sustained release—will require further study to understand the optimal clinical dosing schedule. A slower-release formulation might affect how often a dog needs medication each day.

The technology’s potential extends beyond a single heart drug. The same principle could apply to other medications where precise, small-scale dosing is beneficial, such as thyroid hormones, certain chemotherapy drugs, or medications for managing pain in arthritic pets. It represents a move toward digital, on-demand manufacturing of medications, aligning with broader trends in personalized human and veterinary healthcare. For pet owners, this could one day mean faster access to perfectly dosed medications for their companion’s unique condition.

Conclusion

The successful pharmacokinetic trial of 3D-printed pimobendan in dogs demonstrates that this manufacturing method can produce viable, safe tablets. By enabling precise dose customization, 3D printing offers a tangible solution to improve the management of chronic conditions like canine heart disease, potentially enhancing treatment adherence and outcomes for countless pets.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42184094/
https://pubmed.ncbi.nlm.nih.gov/42182899/
https://pubmed.ncbi.nlm.nih.gov/42180288/